Colloidal bismuth subcitrate is a useful drug in the treatment of peptic ulcerationl-3 but its precise mechanism of action is unknown. Although it is believed to act topically at the ulcer base, low levels of bismuth have been shown in blood and urine of humans4 and in several organs in the laboratory animals5 6 after administration of colloidal bismuth subcitrate, indicating that some absorption does occur. The site of gastrointestinal absorption of colloidal bismuth subcitrate and whether this occurs via the transcellular or paracellular route, are not known. It is possible that uptake by the surface epithelial cells of the stomach and duodenum is inherent in the ulcer healing properties of colloidal bismuth subcitrate.
administration was studied. Mucosal uptake of bismuth (mean ± SEM nmol/g protein) by gastric fundus (8-85+1.0) and antrum (7-23±1.50) was similar, but was significantly less than duodenum (19.2±3.7, p<0-05), jejunum (26.9±2.4, p<0.001) or ileum (22.4±2-2, p<0-001). Bismuth concentrations in antral and duodenal mucosae fell progressively over 72 hours to approximately 10% of initial concentrations (p<0-02). Subcellular fractionation studies of colloidal bismuth subcitrate treated duodenal enterocytes showed a brush border membrane and cytosolic localisation. Tfiese data suggest that some gastrointestinal mucosal uptake of bismuth occurs in colloidal bismuth subcitrate treated rats.
Colloidal bismuth subcitrate is a useful drug in the treatment of peptic ulcerationl-3 but its precise mechanism of action is unknown. Although it is believed to act topically at the ulcer base, low levels of bismuth have been shown in blood and urine of humans4 and in several organs in the laboratory animals5 6 after administration of colloidal bismuth subcitrate, indicating that some absorption does occur. The site of gastrointestinal absorption of colloidal bismuth subcitrate and whether this occurs via the transcellular or paracellular route, are not known. It is possible that uptake by the surface epithelial cells of the stomach and duodenum is inherent in the ulcer healing properties of colloidal bismuth subcitrate.
The aims of the present study are to examine the site and time course of mucosal uptake of bismuth and to determine the subcellular distribution of bismuth within the gastrointestinal mucosa after short term administration of colloidal bismuth subcitrate to rats.
Male Sprague-Dawley rats weighing 200-250 g were kept in mesh bottomed cages to minimise coprophagy. After a 24 hour fast, animals in the treatment group were allowed free access to drinking water containing colloidal bismuth subcitrate, 10 mg/ml (De Nol; Brocades Ltd, UK).
The bismuth content of this solution was found to be 19-0 umol/ml: control animals drank tap water.
[51Cr]-sodium chromate, 1 uCi/ml (3.7 x 104 Bq/ml) (Amersham International, Amersham, Bucks, UK) was added to the drinking water of both groups as a non-absorbable marker.7 After 24 hours, the animals were killed by cervical dislocation. The gastrointestinal tract, from the forestomach to the terminal ileum, was removed in continuity and rinsed five times with ice-cold 150 mmol/l NaCl. The glandular stomach (fundus and antrum), duodenum, jejunum and ileum were isolated and mucosa from each segment scraped off with a glass slide. The mucosa was homogenised in 5 ml deionised distilled water in a 7 ml Dounce homogeniser (Kontes Glass Co., Vineland, NJ, USA) with 10 strokes of a loose-fitting (Type A) pestle, followed by 10 strokes of a tight-fitting (Type B) pestle. A Three additional groups of rats were administered colloidal bismuth subcitrate in the drinking water over 24 hours as outlined above, and subsequently allowed to drink plain water for 24, 48, and 72 hours, respectively, before being killed. Homogenates from gastric antrum and duodenum were prepared and bismuth measured as previously described. Values were corrected for minor variations in total bismuth intake by each animal. Statistical comparison between the groups was made with the use of two-tailed Student's t test.
SUBCELLULAR FRACTIONATION EXPERIMENTS
This was examined in duodenal enterocytes by isopycnic sucrose density centrifugation and microanalysis of organelle marker enzymes, based on the method described by Peters. 10 Rats were given colloidal bismuth subcitrate as a 50 mg/ml solution in the drinking water for 24 hours, and then killed. A higher dose was chosen than that used in the uptake experiments, in order to overcome the dilution effect inherent in the fractionation procedure and to ensure measurable concentrations of bismuth in the subcellular fractions. Duodenal enterocytes were isolated from sacs of duodenal intestine according to Peters and Shio,"1 utilising hyaluronidase (EC 3.2.1.35) and gentle kneading to dislodge the enterocytes from the basement membrane, with subsequent washing of the cell suspension. The enterocytes were immediately transferred to 5 ml ice-cold sucrose solution (0.25 mol/l) containing disodium ethylenediaminetetraacetic acid (Na2 EDTA, 1 mmol/l, pH 7.4) and ethanol (22 mmol/l). The tissue was disrupted on ice in a 7 ml Dounce homogeniser with 10 strokes of pestle A and 10 strokes of pestle B. Approximately 4-5 ml homogenate were layered onto a 28 ml linear sucrose density gradient from 1.05-1 28 g/ml resting on a 6 ml sucrose 1-32 g/ml in a Beaufay automatic zonal rotor. All solutions contained 1 mmol/l, Na2 EDTA, pH 7.4 and 22 mmol/l ethanol. The rotor was then accelerated to 35 000 rev/min for 35 min and then decelerated to 8000 rev/min. The resulting gradient was displaced with nitrogen and 15 fractions collected into tared tubes. After reweighing, the density of each fraction was estimated indirectly with an Abbe refractometer.
Bismuth concentrations and activities of organelle marker enzymes were assayed in each tube and the data presented as frequency-density histograms, as described by Leighton et al. ' 2 The histograms were plotted over a density scale (expressed in g cm-3 of sucrose) and divided into sections of equal density increments. The ordinate expresses the frequency within the corresponding span of density. The lightest fractions (density <1 10 g cm-3) reflect mainly soluble activity remaining in the starting layer, and were plotted over an arbitrary density span of 1-05-1 10 g cm-3. This region, containing the cytosolic enzymes, is separated from the remainder of the gradient (in which the particulate organelle marker enzymes are found) by a vertical line (Fig. 1) . The subcellular localisation of bismuth was determined by comparing its density 'profile' with that of marker enzymes from the various intracellular organelles. In separate experiments, mucosal scrapings were homogenised in sucrose medium containing the selective membrane perturbant digitonin (Sigma Chemical Co), 1 The results are summarised in the Table. In the colloidal bismuth subcitrate-treated animals, bismuth was detected in all mucosal segments. There was no difference between gastric fundus and antrum but bismuth uptake by the small intestinal mucosa was substantially greater than by gastric mucosa. There were no regional differences in bismuth concentration along the small intestine. In none of the homogenates was the 5'Cr more than 4% above background levels, indicating negligible There is little separation between these enzymes, however, and that of the lysosomal marker N-acetyl-,-glucosaminidase. To exclude the possibility of lysosomal accumulation of bismuth, further experiments were performed homogenising the mucosa in the presence of digitonin which forms high-density complexes with membrane-bound cholesterol. Digitonin produced an increase in modal density of the particulate bismuth from 1.23 g/ml to 1*27 g/ml (Fig. 3) . This pattern is characteristically seen with the cholesterol-rich brush border membrane and contrasts markedly with the labilising effect of digitonin on lysosomal membranes. 10 Fig. 2 . Thefrequency-density distribution ofbismuth in control (-) and digitonin-treated (-) homogenates is shown. Digitonin resulted in a shift of the particulate peak from a modal density of1-23 g cm-' to 1-27g cm-3, with no increase in the activity of the soluble component. The data represent the mean oftwo experiments. bismuth in several organs after long term high dose colloidal bismuth subcitrate administration. Low (sub-toxic) bismuth concentrations have also been reported in the blood and urine of human volunteers and patients with peptic ulcers after colloidal bismuth subcitrate therapy for several weeks.4 It is clear, therefore, that some gastrointestinal absorption of bismuth occurs after administration of colloidal bismuth subcitrate.
The results of the present study show uptake of bismuth by both gastric and small intestinal mucosa within 24 hours of starting colloidal bismuth subcitrate administration. This represents intramucosal uptake and not simply adherence of bismuth to the surface mucus, as the tissue was meticulously rinsed and no measurable amounts of the non-absorbable tracer could be detected in the homogenates. It should be pointed out, however, that the doses of colloidal bismuth subcitrate used in this study were high, and that gastrointestinal luminal concentrations of bismuth in this study almost certainly exceeded those achieved therapeutically in ulcer patients.
The relatively lower bismuth concentrations, in gastric compared with small intestinal mucosa, may have resulted from different yields of mucosa and submucosa during tissue harvesting. A more likely explanation, however, is that precipitation of colloidal bismuth subcitrate occurred within the acidic gastric lumen. In contrast, the pH within the intestinal lumen is generally above 4*5 (the pH below which precipitation of colloidal bismuth subcitrate occurs). Wieriks5 found bismuth to be present in the stomach, duodenum, and caecum of rats and dogs after several months of daily dosing with colloidal bismuth subcitrate. In that study, however, bismuth content of the entire wall of the intestine (including adherent mucus) was measured and no comment made about mucosal bismuth concentration.
In the present study, the bismuth content of antral and duodenal mucosa fell progressively over 72 hours after cessation of colloidal bismuth subcitrate administration. This finding could be explained either by gradual systemic absorption of bismuth from the mucosa, or by shedding of bismuth containing cells or their constituents into the lumen during crypt-to-villus maturation.16 Although blood bismuth concentrations were not measured in the present study, the results of the subcellular fractionation experiments clearly show the presence of bismuth within duodenal enterocytes from which it could be absorbed into the circulation. 
